PORTFOLIO

VoxCell is a Victoria, Canada-based biotechnology company building vascularized 3D bioprinted tissue models that replicate the complexity of human tumors for precision oncology drug development. Using its proprietary high-resolution bioprinting platform and bioinks, VoxCell recreates the 3D architecture, vascular networks, and cellular microenvironments of specific cancer types—starting with breast and lung.

These living, patient-relevant tissues enable more predictive efficacy and toxicity testing, helping pharmaceutical and biotech companies better evaluate drug responses, optimize candidate selection, and ultimately reduce the translational gap between preclinical models and human outcomes.

Netri is a Lyon, France-based neurotechnology company developing human nerve-on-chip microphysiological systems that recreate functional neural networks on microfluidic chips to enable predictive, human-relevant neuroscience and toxicology testing. By integrating human-derived neurons, microfluidics, and electrophysiological readouts, Netri provides scalable in-vitro models for applications including chemotherapy-induced peripheral neuropathy (CIPN), neurodegenerative diseases, and CNS drug discovery. Its technology bridges biology and electronics to generate precise, reproducible neural activity data—helping pharmaceutical and biotech partners reduce animal testing, de-risk drug development, and accelerate translation toward safer, more effective therapies.